Close

Corvus Pharmaceuticals (CRVS) PT Raised to $8 at Wedbush, After Clinical Trial Initiated

July 7, 2020 3:55 PM EDT Send to a Friend
Wedbush analyst Robert Driscoll raised the price target on Corvus Pharmaceuticals (NASDAQ: CRVS) to $8.00 (from $5.00) while maintaining a ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE

Member Login